Data Under Review
Some valuation figures for this stock are being recalibrated. Hidden fields will return after data review.
Reported as ticker: NECLIFE· We're continuously improving data quality. Contact support if this persists.
NECTAR LIFESCIENCES LTD.
NECLIFE · General/Diversified · NSE
₹11
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for NECLIFE yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
4/9
Economic Moat
None
Confidence
null%
ROE
-11.9%
Debt/Equity
0.61
WACC
11.1%
Market Cap
₹221.26 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
-1.4%
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
—
Leverage vs earnings
Interest Coverage
-1.1×
EBIT covers interest
Current Ratio
1.21×
Short-term liquidity
Asset Turnover
0.14×
Revenue per ₹ of assets
Revenue CAGR (3Y)
0.0%
3-year revenue growth
Revenue CAGR (5Y)
-6.7%
5-year revenue growth
Ratio Trends
NECLIFE · last 8 annual periods
ROE
-11.9%
ROCE
-1.4%
Operating Margin
—
Debt / Equity
0.61×
PE
18.7×
EV / EBITDA
10.5×
Historical Financials
NECLIFE · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 NSE_XBRL | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1544 Cr | ₹1669 Cr | ₹1524 Cr | ₹1684 Cr | ₹1670 Cr | +2.0% |
| EBITDA | — | ₹161 Cr | ₹99.5 Cr | ₹169 Cr | ₹-22.1 Cr | — |
| EBIT | ₹27.3 Cr | ₹113 Cr | ₹37.1 Cr | ₹105 Cr | — | +40.2% |
| PAT | ₹-73.3 Cr | ₹25.0 Cr | ₹-24.2 Cr | ₹5.0 Cr | ₹-114 Cr | — |
| EPS (diluted) | ₹-3.27 | ₹1.12 | ₹-1.08 | ₹0.22 | — | — |
| CFO | ₹21.4 Cr | ₹95.0 Cr | ₹134 Cr | ₹225 Cr | ₹169 Cr | +67.8% |
| CapEx | — | ₹-25.0 Cr | ₹-30.1 Cr | ₹-29.4 Cr | ₹-43.8 Cr | — |
| FCF | — | ₹70.0 Cr | ₹104 Cr | ₹195 Cr | ₹126 Cr | +15.7% |
| Total Assets | — | ₹2391 Cr | ₹2189 Cr | ₹2191 Cr | ₹2047 Cr | -3.8% |
| Total Debt | — | ₹860 Cr | ₹754 Cr | ₹636 Cr | ₹582 Cr | -9.3% |
| Shareholders' Equity | — | ₹1088 Cr | ₹1065 Cr | ₹1069 Cr | ₹956 Cr | -3.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
NECLIFE vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
AAREYDRUGS AAREYDRUGS | — | — | Pending | 2.6% | — |
BROOKS BROOKS | — | — | Pending | 20.0% | — |
BAFNAPH BAFNAPH | — | — | Pending | 11.5% | — |
MEDICO MEDICO | — | — | Pending | 17.4% | — |
NATCAPSUQ NATCAPSUQ | — | — | Pending | 0.3% | — |
Click a ticker to view its fair-value analysis.
Dividend History
5 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
—
Last payout
2020-09-11
₹0.05
Peak payout
₹0.10
Trailing yield
—
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of NECLIFE →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for NECLIFE →
Compare
Head-to-head with peers
Compare NECLIFE side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse NECLIFENow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.